Large-scale RCTs evaluated sotagliflozin (n = 10,584), canagliflozin (n = 10,142), dapagliflozin (n = 17,160), ertugliflozin (n = 8,246), and canagliflozin (n = 4,401) in T2DM patients with or without CKD and HFpEF, reinforcing the potential role of SGLT2 inhibitors across a range of comorbid conditions [37-41]. This evidence concerns the gene SLC5A2 and chronic kidney disease.